Unknown

Dataset Information

0

Treating rheumatological diseases and co-morbidities with interleukin-1 blocking therapies.


ABSTRACT: The inflammatory cytokines IL-1? and IL-1? orchestrate local and systemic inflammatory responses underlying a broad spectrum of diseases. Three agents for reducing IL-1 activities are currently available. Anakinra is a recombinant form of the naturally occurring IL-1 receptor antagonist. Anakinra binds to the IL-1 receptor and prevents the activity of IL-1? and IL-1?. The soluble decoy receptor rilonacept and the neutralizing mAb canakinumab block IL-1?. A mAb directed against the IL-1 receptor and a neutralizing anti-human IL-1? are in clinical trials. The availability of therapies specifically targeting IL-1 unveiled the pathological role of IL-1-mediated inflammation in a broadening list of diseases. Conditions effectively treated with agents blocking IL-1 range from classic rheumatic diseases, such as RA and gout, to autoinflammatory syndromes, such as systemic JIA and FMF. However, IL-1 antagonism is also effective against highly prevalent inflammatory diseases, namely cardiovascular diseases and type 2 diabetes, conditions that are frequently encountered as co-morbidities in patients with rheumatic diseases. Thereby, IL-1 inhibition has the potential to lift the burden of disease for patients with rheumatic conditions, but also to provide clinical benefits beyond the efficacy on osteoarticular manifestations.

SUBMITTER: Cavalli G 

PROVIDER: S-EPMC5009422 | biostudies-literature | 2015 Dec

REPOSITORIES: biostudies-literature

altmetric image

Publications

Treating rheumatological diseases and co-morbidities with interleukin-1 blocking therapies.

Cavalli Giulio G   Dinarello Charles A CA  

Rheumatology (Oxford, England) 20150723 12


The inflammatory cytokines IL-1α and IL-1β orchestrate local and systemic inflammatory responses underlying a broad spectrum of diseases. Three agents for reducing IL-1 activities are currently available. Anakinra is a recombinant form of the naturally occurring IL-1 receptor antagonist. Anakinra binds to the IL-1 receptor and prevents the activity of IL-1α and IL-1β. The soluble decoy receptor rilonacept and the neutralizing mAb canakinumab block IL-1β. A mAb directed against the IL-1 receptor  ...[more]

Similar Datasets

| S-EPMC3644509 | biostudies-literature
| S-EPMC2713979 | biostudies-literature
| S-EPMC8791232 | biostudies-literature
| S-EPMC3953875 | biostudies-other
| S-EPMC3080043 | biostudies-literature
| S-EPMC3074355 | biostudies-literature
| S-EPMC7347786 | biostudies-literature
| S-EPMC8406988 | biostudies-literature
| S-EPMC5360250 | biostudies-literature
| S-EPMC8088283 | biostudies-literature